2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice

Background

Despite significant advances in prevention and treatment, febrile neutropenia (FN) remains a common and serious complication of chemotherapy. Leverages data related to G-CSF use are missing. This study aims to (1) describe the practices of G-CSF treatment implementation; (2) identify and measure the decision criteria related to their implementation in patients with breast (BC), lung (LC), or gastrointestinal cancers (GIC), in ambulatory settings, beyond the usual recommendations.

Methods

This non-interventional, cross-sectional, multicenter study required clinical cases presented using conversational interfaces (chatbot), simulating a conversation with one or several virtual interlocutors by voice or text exchange.

Results

The questionnaire was completed by 102 physicians. Most practitioners (84.5%) reported prescribing G-CSF, regardless of tumor type (Table). G-CSF was prescribed more frequently for adjuvant/neoadjuvant therapy than for metastatic cases. Leading factors motivating the prescription were chemotherapy regimen, comorbidities, and age (in 56.7% of cases). Access to care was cited as a reason to prescribe G-CSF.

Table: 2047P

Levels and reasons of G-CSF prescription in all 3 cancer types

Conclusions

Our findings suggest that ESMO recommendations are broadly followed. In most cases, G-CSF is prescribed in early stages and in curative intent. Despite a large use of G-CSF, education about febrile neutropenia and risk factors should be disseminated to a wide audience.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Viatris.

Funding

Viatris.

Disclosure

F. Scotté: Financial Interests, Personal, Speaker, Consultant, Advisor: Leo Pharma, Pierre Fabre Oncology, MSD, Amgen, Helsinn, BMS, Pfizer, Thermo Fisher, Alliance Healthcare, Biogaran, Sandoz, Sanofi, Pharmanovia, Viatris.